AB168. Expression and clinical significance of CCAT2 in renal cell carcinoma and bladder cancer

OBJECTIVE: To research the expression of CCAT2 in renal cell carcinoma (RCC), bladder cancer and paired normal tumor-adjacent tissues and investigate the correlations between expression of CCAT2 and clinicopathologic characteristics for further study of the role of CCAT2 in RCC and bladder cancer. METHODS: Total RNA isolated from 40 RCC and 37 bladder cancer tissues and paired normal tumor-adjacent normal tissues which random selected from specimen bank was used for obtaining cDNA by performing reverse transcription. Using real-time PCR (RT-PCR) to detect the expression of CCAT2 in specimen, then using statistical method to analysis the relationships between the expression of CCAT2 and clinicopathologic characteristic. RESULTS: The expression of CCAT2 in RCC tissues was significantly lower than in paired normal tumor-adjacent tissues (P<0.01), with 33 cases (82.5%) showing down-regulation of CCAT2. While the expression of CCAT2 in bladder cancer tissues was significantly higher than in paired normal tumor-adjacent tissues (P<0.01),with 31 cases (83.8%) showing up-regulation of CCAT2.No relationships were found between the expression of CCAT2 and patients’ age, gender, histology, TNM stage or AJCC stage. CONCLUSION: CCAT2 is up-regulated in bladder cancer and down-regulated in RCC, indicating it may participate in the tumorigenesis and development of RCC and bladder cancer and be used as a tumor marker.